34 Obesity and Sexual Dysfunction Trends - 2025

The intersection of obesity and sexual dysfunction represents one of modern medicine's most under-recognized health crises, affecting millions while remaining largely unaddressed in clinical practice. Current research demonstrates that excess weight creates cascading physiological changes that fundamentally alter sexual function through hormonal, vascular, and psychological pathways. We've analyzed peer-reviewed studies, clinical trials, and epidemiological data to present the statistics that illuminate this complex relationship and guide evidence-based treatment decisions. Understanding these connections empowers both patients and providers to address sexual dysfunction as an integral component of comprehensive obesity management.

Key Takeaways

• Men with obesity face nearly double the risk of erectile dysfunction, with moderate to severe cases showing even stronger correlations
• Weight loss interventions demonstrate strong improvements in sexual function with substantial effect sizes for dietary changes
• Waist circumference emerges as a strong predictor, with measurements ≥100 cm significantly increasing ED risk
• Testosterone levels increase following weight loss with notable effect sizes, addressing hormonal contributors to dysfunction
• Even modest weight reduction of 2-5% initial body weight produces measurable improvements in sexual function scores

Prevalence and Risk Factor Analysis

1. Men with obesity have a 1.97 times higher risk of erectile dysfunction, with the risk increasing to 2.71 times for moderate to severe dysfunction

Meta-analysis data quantifies the dose-dependent relationship between excess weight and erectile difficulties, demonstrating that severity matters as much as presence. The nearly threefold risk elevation for moderate to severe ED indicates that obesity doesn't just increase dysfunction likelihood—it intensifies the degree of impairment when problems develop. This graduated risk profile reflects obesity's progressive damage to vascular endothelium, testosterone production, and neural pathways essential for erectile function. The statistics translate to millions of affected men who might benefit from our chewable ED treatments that address the vascular component while patients work on weight management. Understanding this risk multiplication helps men recognize ED as an early warning sign of obesity-related health consequences requiring comprehensive intervention.

2. Men with cardiovascular disease and obesity experience extremely high rates of erectile dysfunction

Cardiovascular comorbidity research reveals near-universal sexual dysfunction when obesity combines with cardiovascular disease. This statistic underscores how multiple risk factors create synergistic effects far exceeding their individual contributions. The findings suggest that once cardiovascular damage occurs, even modest excess weight significantly impairs erectile function. For men with these conditions, this data emphasizes the importance of aggressive risk factor modification and early pharmaceutical intervention to preserve sexual function. The overwhelming prevalence in this population validates the need for proactive treatment approaches.

3. Men with a waist circumference of ≥100 cm have 3.74 times higher odds of developing erectile dysfunction

Anthropometric studies identify central adiposity as a particularly potent predictor of sexual dysfunction, surpassing BMI in predictive power. This nearly fourfold risk increase reflects visceral fat's unique metabolic activity, producing inflammatory cytokines and hormonal disruptions that directly impair erectile function. The waist circumference threshold provides a simple, actionable screening tool that men can monitor independently without complex calculations. Central obesity's strong association with insulin resistance and endothelial dysfunction explains why fat distribution matters more than total weight for sexual health outcomes. Our comprehensive approach addresses these vascular consequences through medications that enhance blood flow while patients work on reducing abdominal adiposity.

Treatment Response and Weight Loss Impact

4. Weight loss interventions show strong improvement in sexual desire scores with substantial effect sizes for dietary interventions

Systematic review evidence quantifies the benefits achievable through structured weight reduction programs on sexual function, with dietary interventions showing effect sizes around 1.16 for sexual desire improvement. An effect size exceeding 1.0 represents a large clinical impact by statistical standards, translating to meaningful real-world improvements in desire, arousal, and satisfaction. The specific success of dietary interventions suggests that nutritional quality and caloric balance directly influence hormonal and vascular factors underlying sexual dysfunction. This data provides hope that non-surgical approaches can achieve significant benefits when properly implemented and sustained. The magnitude of improvement rivals pharmaceutical interventions for some aspects of sexual dysfunction, validating lifestyle modification as first-line therapy while using medications like our TAD for immediate symptom relief during the weight loss journey.

5. Bariatric surgery shows strong effect sizes for sexual desire improvement, slightly exceeding dietary interventions

Surgical outcome research demonstrates that dramatic weight loss through bariatric procedures produces correspondingly dramatic sexual function improvements, with effect sizes around 1.22 for desired outcomes. The marginally higher effect size compared to dietary interventions likely reflects greater absolute weight loss and more rapid hormonal normalization following surgery. However, the comparable effectiveness suggests that surgery's benefits primarily stem from weight reduction rather than unique surgical effects. This finding empowers patients to choose interventions based on individual circumstances rather than assuming surgery provides categorically superior sexual health outcomes. The rapid improvements following bariatric surgery—often within months—validate addressing sexual dysfunction early in the weight loss process rather than waiting for goal weight achievement.

6. Sexual dysfunction prevalence decreases substantially following bariatric surgery in longitudinal cohort studies

Longitudinal surgical studies from specific cohorts document significant relative reductions in sexual dysfunction following successful weight loss surgery. These improvements encompass multiple domains, including desire, arousal, lubrication, and orgasm, reflecting comprehensive physiological restoration rather than isolated symptomatic improvement. The persistence of dysfunction in some patients post-surgery indicates that obesity-related sexual changes may require additional interventions beyond weight loss alone. The timeline of improvement—typically 6-12 months post-surgery—aligns with hormonal normalization and metabolic recovery patterns. These statistics guide realistic expectation setting while validating surgical intervention for patients with severe obesity and sexual dysfunction.

7. Most bariatric surgery patients remain sexually active both before and after weight loss surgery

Patient behavior studies reveal that the majority of individuals maintain sexual activity despite obesity-related challenges, contradicting assumptions about complete sexual withdrawal. This statistic highlights human resilience and adaptation while emphasizing that sexual activity doesn't equate to sexual satisfaction or optimal function. The consistency before and after surgery suggests that weight loss improves the quality rather than the frequency of sexual encounters for most patients. Understanding this distinction helps healthcare providers focus on enhancing sexual satisfaction and function rather than simply encouraging sexual activity. The data validates comprehensive approaches addressing both physical function and psychosocial factors affecting sexual well-being.

Hormonal and Metabolic Mechanisms

8. Testosterone levels increase substantially following dietary weight loss interventions in men

Hormonal recovery studies quantify the profound impact of weight loss on male hormonal profiles, with improvements showing effect sizes around 1.39. This large effect size translates to clinically meaningful testosterone increases that restore libido, erectile function, and overall vitality. The mechanism involves reduced aromatase activity in adipose tissue, decreased inflammatory suppression of testicular function, and improved hypothalamic-pituitary signaling. Weight loss-induced testosterone recovery offers a natural alternative to hormone replacement therapy for many men with obesity-related hypogonadism.

9. Approximately 45% of men with moderate-severe obesity develop male obesity secondary hypogonadism (MOSH)

Endocrine research identifies a specific hormonal syndrome affecting nearly half of significantly obese men, characterized by low testosterone despite normal testicular anatomy. This condition creates a vicious cycle where low testosterone promotes further weight gain and metabolic dysfunction, perpetuating both obesity and sexual dysfunction. MOSH differs from primary hypogonadism in its potential reversibility with weight loss, offering hope for hormonal restoration without lifelong replacement therapy. The high prevalence validates routine testosterone screening in obese men with sexual dysfunction rather than attributing symptoms solely to mechanical or vascular factors. Understanding MOSH helps explain why some men require combination approaches addressing both hormonal and vascular components of erectile dysfunction.

10. Longitudinal studies show weight gain trajectory correlates with reduced sexual desire and less frequent intercourse

Longitudinal cohort studies demonstrate that weight gain trajectory matters as much as absolute weight for sexual health outcomes. This finding suggests that rapid or unexpected weight gain creates acute metabolic disruptions beyond those seen with stable obesity, potentially overwhelming adaptive mechanisms. The correlation with both desire and behavior indicates that weight gain affects multiple aspects of sexuality, including psychological, hormonal, and physical domains. For individuals experiencing recent weight gain, this data emphasizes the importance of early intervention before dysfunction patterns become entrenched. The temporal relationship also validates addressing weight stability as part of comprehensive sexual health management.

11. Testosterone therapy shows variable results in hypogonadal men with ED

Hormone replacement studies reveal that a subset of hypogonadal men experience ED improvement with testosterone therapy, though response rates vary significantly. The variable response indicates that obesity-related ED involves complex mechanisms beyond simple testosterone deficiency, requiring multimodal treatment approaches. This finding challenges the assumption that hormone replacement alone can restore sexual function in obese men, emphasizing the need for comprehensive treatment strategies. The data support combining hormonal optimization with PDE5 inhibitors for enhanced outcomes. Our Max Combo addresses multiple pathways simultaneously, potentially benefiting those who don't respond to monotherapy.

12. Large-scale meta-analysis demonstrates a consistent association between BMI and sexual desire across diverse populations

Large-scale meta-analysis provides robust evidence that weight-related sexual dysfunction transcends cultural, ethnic, and geographic boundaries. The massive sample sizes ensure statistical power to detect even subtle effects while confirming consistency across diverse populations. This universal relationship suggests fundamental biological mechanisms rather than culturally mediated associations, validating obesity as a legitimate medical cause of sexual dysfunction globally. The specific impact on desire—often considered primarily psychological—demonstrates obesity's profound effects on neurohormonal pathways regulating libido. Understanding this biological basis helps reduce stigma and encourages medical treatment seeking for weight-related sexual problems.

Cardiovascular and Metabolic Connections

13. Men with cardiovascular disease and obesity experience extremely high rates of ED

Cardiovascular comorbidity studies demonstrate near-universal sexual dysfunction when multiple vascular risk factors converge. This extreme prevalence reflects shared pathophysiology between cardiovascular disease and erectile dysfunction, with obesity amplifying both conditions. The finding positions ED as a cardiovascular risk marker, warranting aggressive risk factor modification and preventive strategies. For affected men, this data normalizes their experience while emphasizing that treatment remains possible despite multiple comorbidities. Our TAD chewables work through vascular mechanisms that support erectile function improvement.

14. Insulin resistance markers correlate directly with sexual dysfunction severity in both genders

Metabolic syndrome research establishes insulin resistance as a central mechanism linking obesity to sexual dysfunction across populations. This correlation suggests that improving insulin sensitivity through weight loss, exercise, or medication may enhance sexual function independent of weight change. The finding provides a biological rationale for comprehensive metabolic management in sexual dysfunction treatment. Insulin resistance affects vascular function, hormone production, and neural signaling—all critical for sexual response. Understanding this mechanism helps explain why metabolic improvements often precede weight loss in restoring sexual function.

15. Inflammatory markers, including leptin, show strong associations with erectile dysfunction risk

Inflammatory pathway studies identify specific molecular mechanisms through which adipose tissue impairs the sexual function systemically. Leptin resistance, characteristic of obesity, directly suppresses testosterone production while promoting vascular inflammation. These inflammatory mediators create a hostile environment for erectile function, requiring anti-inflammatory strategies alongside traditional ED treatments. The finding suggests that interventions reducing inflammation—through diet, exercise, or medication—may enhance sexual function recovery. Our comprehensive approach addresses the vascular consequences of inflammation while patients work on reducing the inflammatory burden through lifestyle changes.

16. Oxidative stress from obesity contributes to endothelial dysfunction underlying most ED cases

Molecular mechanism research reveals how excess adipose tissue generates reactive oxygen species that damage the blood vessel lining, crucial for erections. This oxidative damage accumulates over time, potentially explaining why sexual dysfunction worsens with obesity duration. Antioxidant strategies through diet and supplementation may complement traditional ED treatments by addressing underlying vascular damage. The mechanism links obesity-related ED to broader cardiovascular disease processes, emphasizing systemic health implications. Understanding oxidative stress helps explain why some patients require extended treatment before seeing improvement.

Population Patterns and Considerations

17. ED prevalence increases progressively across the lifespan in the general population

Population-based epidemiology demonstrates the progressive nature of erectile dysfunction across the lifespan, with obesity accelerating this trajectory. The baseline prevalence in younger populations challenges assumptions that ED primarily affects older individuals, suggesting modern lifestyle factors contribute significantly. The progressive increase reflects accumulated vascular damage, hormonal decline, and comorbidity development. For obese men, these changes compound weight-related dysfunction, creating an earlier onset and greater severity. Early intervention may prevent progression to severe dysfunction in later years.

18. Combined psychological and medical intervention shows high success rates in obese men with ED

Treatment outcome data reveal excellent outcomes when addressing both psychological and physical factors in obese populations. High success rates reflect the reversibility of early-stage dysfunction before permanent vascular or neural damage occurs. Obesity-related ED often involves performance anxiety amplified by body image concerns, requiring comprehensive approaches. The finding validates aggressive early intervention rather than watchful waiting in men with obesity-related sexual dysfunction. Combined treatment prevents progression to more entrenched dysfunction patterns requiring intensive intervention.

19. Treatment-seeking behavior peaks during middle years despite ED continuing to increase with advancing years

Healthcare utilization patterns reveal that men in their middle years are most likely to seek help for obesity-related sexual dysfunction, representing an intervention opportunity. This group often has established relationships, financial resources, and motivation to maintain sexual function during peak life years. The treatment-seeking decline in later years despite higher prevalence suggests resignation or access barriers requiring targeted outreach. Understanding these patterns helps optimize service delivery and marketing for appropriate interventions. Our telehealth platform removes many barriers that prevent men from seeking treatment.

Lifestyle Modification Impact

20. Lifestyle modifications alone improve erectile function in a subset of men with mild obesity-related ED

Behavioral intervention trials establish that some men with early-stage dysfunction can restore function through weight loss and exercise alone. This validates lifestyle modification as first-line therapy for mild cases while identifying those who require pharmaceutical support. The responders typically show rapid improvement within 3-6 months, suggesting that early dysfunction remains highly reversible. Non-responders shouldn't be considered failures but rather identified as needing multimodal therapy for optimal outcomes. We support lifestyle modification with immediate symptom relief through our medications, maximizing both short and long-term outcomes.

21. Mediterranean diet adoption shows independent benefits for sexual function beyond weight loss effects

Nutritional intervention research demonstrates that dietary quality influences sexual health through mechanisms beyond caloric balance and weight reduction. The Mediterranean diet's anti-inflammatory effects, endothelial benefits, and favorable lipid modifications directly enhance erectile function. This finding suggests that dietary counseling should emphasize food quality alongside quantity for optimal sexual health outcomes. Specific nutrients, including omega-3 fatty acids, antioxidants, and nitric oxide precursors, support vascular and hormonal health. Combining dietary optimization with appropriate ED medications creates synergistic benefits exceeding either intervention alone.

22. Regular physical activity reduces ED risk by approximately 30% independent of weight loss in obese men

Exercise intervention studies reveal that movement provides sexual health benefits beyond its contribution to weight management. Exercise improves endothelial function, increases testosterone, reduces inflammation, and enhances psychological well-being—all supporting sexual function. The protective effect occurs with moderate activity levels achievable by most obese individuals, not requiring extreme fitness. This finding encourages physical activity even when weight loss plateaus, maintaining motivation through continued functional improvements. Regular exercise enhances medication effectiveness, potentially allowing optimized dosing or improved response rates.

23. Sleep apnea treatment in obese patients improves erectile function independent of weight change

Sleep disorder intervention research identifies sleep quality as a modifiable factor affecting sexual function in obesity. CPAP therapy for obstructive sleep apnea improves nocturnal erections, testosterone levels, and endothelial function without requiring weight loss. This finding emphasizes comprehensive obesity management addressing all comorbidities rather than weight alone. Many obese men have undiagnosed sleep apnea, contributing to sexual dysfunction, representing a treatable component. Improved sleep quality enhances energy and mood, supporting both sexual function and weight loss efforts.

Surgical and Advanced Interventions

24. Studies show substantial reductions in sexual dysfunction prevalence following bariatric surgery

Surgical outcome tracking quantifies the substantial but incomplete resolution of sexual problems following dramatic weight loss. Significant relative reductions validate surgery as an effective intervention while acknowledging persistent dysfunction in some patients. Residual dysfunction may reflect irreversible changes, body image concerns, or relationship factors unaffected by weight loss. The improvement timeline varies, with some experiencing immediate benefits while others require months for hormonal normalization. Post-surgical sexual health support optimizes outcomes through counseling, medical management, and relationship therapy as needed.

25. Bariatric surgery patients show substantial testosterone increases within 12 months

Hormonal recovery studies document testosterone restoration following surgical weight loss in men. These increases often move patients from hypogonadal to normal ranges, potentially eliminating the need for hormone replacement therapy. The magnitude and speed of recovery exceed typical results from lifestyle modification alone, reflecting surgery's dramatic metabolic impact. Testosterone recovery correlates with improved sexual function, but some men require additional ED treatment despite hormonal normalization. We provide continued support for post-bariatric patients who need pharmaceutical assistance during recovery or for residual dysfunction.

26. Sexual activity patterns show modest improvements after bariatric surgery

Sexual behavior changes following weight loss surgery demonstrate meaningful increases in sexual engagement. The improvements reflect enhanced physical capability, confidence, and relationship dynamics post-surgery. However, many maintain sexual activity throughout, suggesting that obesity doesn't universally prevent sexual expression despite causing dysfunction. The behavioral change occurs gradually, often requiring psychological adjustment to body changes and relationship renegotiation. Supporting this transition involves addressing body image, intimacy fears, and partner communication alongside physical recovery.

Treatment Accessibility and Adherence

27. According to the 2021 National Survey of Sexual Wellbeing, only 7.7% of men with ED symptoms receive a professional diagnosis

Healthcare utilization analysis reveals that over 92% of men experiencing erectile dysfunction never receive medical evaluation or treatment, with only 16.7% discussing symptoms with a clinician. This diagnostic gap particularly affects obese men who may face additional stigma and access barriers. Undiagnosed ED represents missed opportunities for cardiovascular risk detection and metabolic syndrome identification. Traditional healthcare delivery, requiring in-person consultations, perpetuates this treatment gap. Our telehealth platform directly addresses these barriers through private online consultations and discreet home delivery, making professional care accessible to previously underserved populations.

28. Partner involvement improves ED treatment adherence and outcomes in obese men

Relationship studies demonstrate that including partners in treatment planning enhances outcomes and satisfaction. Partner support helps maintain motivation during challenging weight loss periods while normalizing medical treatment for sexual issues. Many partners feel relieved when ED is addressed medically rather than attributed to relationship problems. Couple-based approaches address communication, intimacy, and lifestyle changes affecting both individuals. We encourage partner participation in treatment decisions while maintaining patient privacy and autonomy.

29. ED medication costs can create significant financial barriers for consistent treatment

Healthcare economics analysis reveals that medication costs often create barriers to consistent ED treatment for many men. Financial burden contributes to treatment discontinuation and suboptimal dosing, particularly affecting obese patients managing multiple health conditions. Cost concerns delay treatment seeking, allowing dysfunction to worsen and become harder to treat. Our subscription model starting at affordable monthly rates makes consistent treatment accessible regardless of economic status.

30. Telehealth platforms reduce ED treatment barriers by eliminating travel and time costs

Healthcare delivery research demonstrates that remote consultation models dramatically improve treatment accessibility. Eliminated barriers include transportation, time off work, and geographic distance to specialists—particularly important for obese patients with mobility limitations. Telehealth consultations reduce embarrassment through private, home-based interactions while maintaining medical quality. The convenience factor improves treatment initiation and adherence, especially for busy professionals and rural residents. Our platform maximizes these advantages while providing ongoing medical support and convenient chewable medications delivered directly to patients' homes.

Combined Treatment Approaches

31. Combination therapy approaches show significant improvements over monotherapy in treatment-resistant cases

Combination treatment trials reveal benefits from multimodal pharmaceutical approaches in treatment-resistant cases, though routine combination of multiple PDE5 inhibitors requires careful medical supervision. Meta-analyses show improvements when adding adjunct therapies to PDE5 inhibitors. These approaches particularly benefit obese men with severe vascular compromise requiring comprehensive pharmaceutical support. Success requires careful medical supervision to optimize dosing and monitor for safety. Our MAX and VMAX formulations provide pre-optimized combinations in single tablets under appropriate medical oversight.

32. Weight loss combined with ED medication shows high success rates in obesity-related ED with psychological components

Integrated treatment studies demonstrate superior outcomes when addressing both physical and psychological factors simultaneously. Many obese men develop performance anxiety secondary to weight-related ED, creating self-perpetuating dysfunction cycles. Combined treatment breaks these cycles through immediate pharmaceutical relief while building confidence through weight loss success. The approach validates comprehensive care addressing all dysfunction contributors rather than assuming single causation. Our medications provide reliable function while patients work on underlying weight and psychological factors.

33. Daily low-dose PDE5 inhibitors plus lifestyle modification outperform either approach alone

Treatment optimization research establishes that continuous medication combined with weight loss produces optimal outcomes. Daily dosing maintains vascular health while lifestyle changes address root causes, creating complementary benefits. This approach particularly suits obese men in stable relationships seeking consistent function without timing concerns. The combination often allows eventual medication optimization as weight loss progresses, though many choose to continue for maintained benefits. Our DailyTAD provides convenient daily therapy for comprehensive health optimization.

34. Multimodal approaches including mechanical devices with medication can benefit severe obesity-related ED

Multimodal therapy studies show that vacuum devices can enhance pharmaceutical treatment in challenging cases. The combination addresses both arterial inflow and venous occlusion problems common in severe obesity-related dysfunction. While more complex than medication alone, this approach helps men avoid surgical interventions. Success requires patient education and commitment but provides reliable function when simpler approaches fail. We focus on optimizing pharmaceutical therapy first while recognizing devices' role in comprehensive treatment planning.

The Path Forward

These statistics paint a sobering yet ultimately hopeful picture of obesity's impact on sexual health. With prevalence rates varying significantly across populations and clear dose-response relationships between weight and dysfunction severity, the scope of this health crisis demands urgent attention. Yet the data also reveals remarkable treatment responsiveness—from substantial reductions in dysfunction following bariatric surgery to significant effect sizes for various weight loss interventions.

The evidence demonstrates that sexual dysfunction represents both a consequence and potential motivator for obesity treatment. Understanding these connections empowers healthcare providers to address sexual health proactively while helping patients recognize dysfunction as a reversible medical condition rather than personal failure. The strong improvements seen with even modest 2-5% weight loss provide achievable initial goals that build momentum toward comprehensive health restoration.

Perhaps most importantly, these statistics validate multi-modal treatment approaches combining weight management with appropriate medical therapy. We developed our platform specifically to support this comprehensive strategy, providing immediate relief through proven medications while patients pursue longer-term weight loss goals. By removing traditional barriers to treatment and offering multiple formulation options, we help bridge the gap between the over 90% of men with undiagnosed ED and the effective treatments modern medicine provides.

Frequently Asked Questions

Can losing weight permanently cure erectile dysfunction caused by obesity?

Weight loss can significantly improve or resolve obesity-related erectile dysfunction, with dietary interventions showing substantial effect sizes and bariatric surgery achieving strong improvements for sexual function. However, complete resolution depends on multiple factors, including weight loss amount, the duration of dysfunction, and the presence of irreversible vascular damage. Studies show significant reductions in sexual dysfunction after bariatric surgery, indicating substantial but not universal improvement. Even modest weight loss of 2-5% produces measurable benefits, though many men benefit from continued medical support through treatments like our chewable ED medications during and after weight loss.

What percentage of obese men experience sexual dysfunction?

Research demonstrates that men with obesity have a 1.97 times higher risk of erectile dysfunction, with risk increasing to 2.71 times for moderate to severe cases. When examining specific populations with both obesity and cardiovascular disease, extremely high rates of ED are observed. Additionally, 45% of men with moderate-severe obesity develop male obesity secondary hypogonadism (MOSH), contributing to sexual dysfunction. Central obesity proves particularly problematic, with waist circumference ≥100cm increasing ED odds by 3.74 times.

How quickly can weight loss improve sexual function?

Sexual function improvements can occur rapidly with weight loss, often preceding significant body composition changes. Studies show testosterone levels increasing substantially following dietary interventions, with hormonal improvements typically visible within 8-12 weeks. Bariatric surgery patients show testosterone increases within 12 months, though some improvements begin within weeks of surgery as metabolic changes occur.

Are ED medications safe for obese patients?

ED medications remain safe and effective for obese patients, with diabetic patients achieving 56-72% success rates when properly managed despite complex health conditions. However, patients with multiple comorbidities often require individualized dosing for optimal response and safety. The key consideration involves potential interactions with obesity-related medications and cardiovascular conditions rather than obesity itself. Combination therapy approaches can show improvements in treatment-resistant cases, though this requires careful medical supervision. Our platform provides a comprehensive medical evaluation to ensure safe, appropriate treatment selection for obese patients.

This article is for informational purposes only and does not constitute medical advice. The content provided here is not a substitute for, and should never be relied upon as, professional medical advice. Always consult your doctor to discuss the risks, benefits, and appropriateness of any treatment. BlueChew offers compounded medications prescribed solely for the treatment of erectile dysfunction and sexual performance enhancement. Compounded medications are not FDA-approved.